Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma?

Journal of Viral Hepatitis

Volumn 14, Issue 2, 2007, Pages 96-106

  Vallet, S ^a,b   Gouriou, S ^b   Nkontchou, G ^c   Hotta, H ^e   Vilerio, M ^b   Legrand Quillien, M C ^a   Beaugrand, M ^c   Trinchet, J C ^c   Nousbaum, J B ^d   Deny P ^c   Gaudy, C ^b   Goudeau, A ^b   Picard, B ^c   Payan, C ^a,b  

^a CHU MORVAN   (France)

^b UNIVERSITÉ DE BREST   (France)

^c CH JVerdier ^*  (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma; NS3 protease; Polymorphism; Quasispecies

Indexed keywords

MUTANT PROTEIN; NONSTRUCTURAL PROTEIN 3; VIRUS PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROSIS; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN VARIANT; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33846431257     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00773.x     Document Type: Article

References (48)

1. Degos F, Christidis C, Ganne-Carrie N et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136.
2. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 1994; 68: 5045-5055.
3. Eckart MR, Selby M, Masiarz F et al. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun 1993; 192: 399-406.
4. Gallinari P, Brennan D, Nardi C et al. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 1998; 72: 6758-6769.
5. Failla C, Tomei L, De Francesco R. An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J Virol 1995; 69: 1769-1777.
6. Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 2004; 39: 554-567.
7. Smith RM, Wu GY. Structure-based design of hepatitis C virus inhibitors. J Viral Hepat 2003; 10: 405-412.
8. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69: 3893-3896.
9. Zemel R, Gerechet S, Greif H et al. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat 2001; 8: 96-102.
10. Fujita T, Ishido S, Muramatsu S, Itoh M, Hotta H. Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. Biochem Biophys Res Commun 1996; 229: 825-831.
11. Ishido S, Hotta H. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett 1998; 438: 258-262.
12. Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 2001; 82: 2235-2241.
13. Ogata S, Florese RH, Nagano-Fujii M et al. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol 2003; 41: 2835-2841.
14. Ogata S, Ku Y, Yoon S, Makino S, Nagano-Fujii M, Hotta H. Correlation between secondary structure of an amino-terminal portion of the nonstructural protein 3 (NS3) of hepatitis C virus and development of hepatocellular carcinoma. Microbiol Immunol 2002; 46: 549-554.
15. Martell M, Esteban JI, Quer J et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-3229.
16. Smith DB, McAllister J, Casino C, Simmonds P. Virus 'quasispecies': making a mountain out of a molehill? J Gen Virol 1997; 78 (Pt. 7): 1511-1519.
17. Gomez J, Martell M, Quer J, Cabot B, Esteban JI. Hepatitis C viral quasispecies. J Viral Hepat 1999; 6: 3-16.
18. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
19. Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
20. Roque-Afonso AM, Ferey MP, Poveda JD, Marchadier E, Dussaix E. Performance of TRUGENE hepatitis C virus 5′ noncoding genotyping kit: a new CLIP sequencing-based assay for hepatitis C virus genotype determination. J Viral Hepat 2002; 9: 385-389.
21. Laperche S, Lunel F, Izopet J et al. Comparison of hepatitis C virus NS5b and 5′ noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 2005; 43: 733-739.
22. Holland-Staley CA, Kovari LC, Golenberg EM, Pobursky KJ, Mayers DL. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 2002; 147: 1385-1406.
23. Lodrini S, Bagaglio S, Canducci F et al. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J Biol Regul Homeost Agents 2003; 17: 198-204.
24. Staden R, Beal KF, Bonfield JK. The Staden package, 1998. Methods Mol Biol 2000; 132: 115-130.
25. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. Multiple sequence alignment with Clustal X. Trends Biochem Sci 1998; 23: 403-405.
26. Nicholas KB, Nicholas HB, Jr, Deerfield, DW. GeneDoc: analysis and visualization of genetic variation. Embnew News 1997; 4: 14.
27. Wolinsky SM, Korber BTM, Neumann AU et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996; 272: 537-542.
28. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986; 3: 418-426.
29. Kumar S, Tamura K, Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004; 5: 150-163.
30. Garnier J, Osguthorpe DJ, Robson B. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 1978; 120: 97-120.
31. Salemi M, Vandamme AM. Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol 2002; 54: 62-70.
32. Kim JL, Morgenstern KA, Lin C et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-355.
33. Kato N, Hijikata M, Ootsuyama Y et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-9528.
34. Lin C, Lin K, Luong YP et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-17514.
35. Lu L, Pilot-Matias TJ, Stewart KD et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48: 2260-2266.
36. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 1999; 6: 165-181.
37. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol 2005; 75: 528-537.
38. Poynard T, Mathurin P, Lai CL et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257-265.
39. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
40. Vallet S, Nousbaum JB, Gouriou S, Legrand-Quillien MC, Goudeau A, Picard B. A particular hepatitis C virus protease NS3 gene pattern in a patient not responding to interferon-ribavirin therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 79-80.
41. Gao G, Stuver SO, Okayama A, Tsubouchi H, Mueller NE, Tabor E. The minimum number of clones necessary to sequence in order to obtain the maximum information about hepatitis C virus quasispecies: a comparison of subjects with and without liver cancer. J Viral Hepat 2005; 12: 46-50.
42. Koizumi K, Enomoto N, Kurosaki M et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22: 30-35.
43. Curran R, Jameson CL, Craggs JK et al. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 2002; 83: 11-23.
44. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL Jr, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70: 7622-7631.
45. Ogata S, Nagano-Fujii M, Ku Y, Yoon S, Hotta H. Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol 2002; 40: 3625-3630.
46. Gimenez-Barcons M, Franco S, Suarez Y et al. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology 2001; 34: 158-167.
47. Franco S, Gimenez-Barcons M, Puig-Basagoiti F et al. Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. J Med Virol 2003; 71: 195-204.
48. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 3392-3396.